All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the EHA2021 Virtual Congress, the AML Hub spoke with Jannik Stemler, University Hospital Cologne, Cologne, DE. We asked, Should antifungal prophylaxis be used in patients with AML who are treated with novel agents?
Should antifungal prophylaxis be used in patients with AML who are treated with novel agents?
In this video, Stemler discusses antifungal prophylaxis in adult patients with high risk AML treated with novel agents. He emphasizes the improvement in overall- and progression-free survival of patients that undergo intensive chemotherapy treatment in combination with antifungal therapy. Finally, Stemler touches upon drug-drug interactions, dosage, and the role of therapeutic monitoring.
EHA2021 abstracts: What’s hot in AML?
To help navigate the exciting content being presented at the EHA2021 Virtual Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML,...
What is the real-world experience of R/R AML treatment with venetoclax + HMAs?
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory...
Subscribe to get the best content related to AML delivered to your inbox